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TGF-b1 dissociates human proximal tubule cell growth and Na
1-H1
exchange activity. Stimulation of proximal tubule cell (PTC) growth in a
variety of physiological and pathological renal conditions is preceded by
increased renal production of transforming growth factor-b1 (TGF-b1)
and by augmented tubular sodium transport via activated sodium hydro-
gen exchange (NHE). Since TGF-b1 has been shown to be an important
paracrine and autocrine regulator of PTC growth, the hypothesis that
TGF-b1 modulates basal and mitogen-stimulated PTC growth via an effect
on NHE activity was examined. Confluent, quiescent, human PTC were
incubated for 24 hours in serum-free media containing vehicle (control) or
1 ng/ml TGF-b1, in the presence or absence of 100 ng/ml insulin-like
growth factor-1 (IGF-I). Under basal conditions, TGF-b1 inhibited thy-
midine incorporation (73.5 6 7.3% of control, P , 0.05), but exerted no
effect on cellular protein content (97.4 6 10.7% of control), an index of
hypertrophy. There was no significant alteration of NHE activity, mea-
sured as ethylisopropylamiloride (EIPA)-sensitive H1 efflux (2.72 6 0.50
vs. control 3.26 6 0.68 mmol/liter/min) or 22Na1 influx (2.20 6 0.23 vs.
control 2.19 6 0.19 nmol/mg protein/min). When co-incubated with IGF-I,
TGF-b1 induced significant PTC hypertrophy (116.9 6 8.2% of control,
P , 0.05), which was not seen with either agent alone. TGF-b1 counter-
acted the stimulatory effect of IGF-I on DNA synthesis (TGF-b11IGF-I
103.0 6 7.3% vs. IGF-I alone 181.2 6 30.3% of control, P , 0.05), but did
not affect IGF-I-stimulated EIPA-sensitive 22Na1 influx (3.63 6 0.63 vs.
IGF-I alone 3.67 6 0.50 nmol/mg protein/min, P 5 NS, both vs. control
2.19 6 0.19 nmol/mg protein/min, P , 0.05). Similar results were obtained
when NHE activity was measured as EIPA-sensitive H1 efflux. Moreover,
the kinetics of NHE activation by the combination of TGF-b1 and IGF-I
(involving an increase in Vmax) were identical to that previously found for
PTC exposed to IGF-I alone. The study demonstrates that TGF-b1 elicits
distinct PTC growth responses in the presence and absence of IGF-I,
without modification of NHE activity. The combination of predominant
PTC hypertrophy and enhanced proximal tubule Na1 reabsorption found
in many conditions that are associated with renal growth is likely to
require the integrated actions of both TGF-b1 and IGF-I.
Loss of functional renal tissue, due either to renal disease or
surgical ablation, is followed by augmented proximal tubule
transport and proximal tubule cell (PTC) hypertrophy [1]. Al-
though such changes serve to compensate for reduced nephron
numbers and help to maintain glomerulotubular balance in the
short term, excessive stimulation of PTC growth and transport
function may ultimately be maladaptive [2]. The development of
therapeutic strategies aimed at limiting this hypertrophic growth
response requires further knowledge of the factors that regulate,
or dysregulate, this growth response.
Transforming growth factor-b (TGF-b), a multi-functional cy-
tokine produced by tubular, interstitial and glomerular cells, is
now recognized as a key player in the regulation of PTC growth
[3]. Increased renal TGF-b expression has been observed in
animal models of physiological and pathological renal growth,
including compensatory hypertrophy [4], subtotal nephrectomy
[3], adriamycin nephropathy [5] and streptozotocin-induced dia-
betic nephropathy [6, 7]. TGF-b over-expression has also been
documented in renal tissue obtained from patients with diabetic
nephropathy, focal segmental glomerulosclerosis, IgA nephropa-
thy, human immunodeficiency virus nephropathy and chronic
renal allograft rejection [3, 8]. All are conditions where the
tubulointerstitial growth response is the primary predictor of
kidney failure [2, 9]. In vitro studies in animal PTC provide specific
evidence that TGF-b promotes hypertrophy, either alone [10, 11]
or in combination with mitogens, such as insulin [12] and epider-
mal growth factor (EGF) [13]. Moreover, Sharma and colleagues
[7] demonstrated that treatment of diabetic rats with neutralizing
anti-TGF-b antibodies substantially reduces PTC hypertrophy.
Despite links between other growth factors and transport [14,
15], little attention has been directed towards the specific effects
of TGF-b on PTC transport processes. Proximal tubule sodium-
hydrogen exchange (NHE) activity and sodium reabsorption have
been shown to increase prior to the onset of compensatory renal
hypertrophy [16, 17], and to be potentially linked to cell growth
[18, 19] and subsequent hypermetabolic cellular injury [20]. We
have previously demonstrated the key role of insulin-like growth
factor-1 (IGF-I) in stimulating PTC mitogenesis and NHE [14].
As TGF-b and IGF-I are likely to have integrated effects on renal
growth and transport, the effects of transforming growth factor-b1
(TGF-b1) on human proximal tubule growth parameters and
NHE activity were determined under basal and IGF-I-stimulated
conditions.
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METHODS
Patients
Segments of macroscopically and histologically normal renal
cortex were obtained aseptically from adult human kidneys re-
moved surgically because of small (,6 cm) renal adenocarcino-
mas (N 5 6), pelvic transitional cell carcinoma (N 5 1) or
angiomyolipoma (N 5 1). The average patient age was 62.3 6 4.3
years (mean 6 SEM) and the male:female ratio was 3:5. Patients
were otherwise healthy and were on no medications. Informed
consent was obtained prior to their operation and the use of
human renal tissue for primary culture was reviewed and ap-
proved by the Royal North Shore Hospital and University of
Sydney Human Medical Research Ethics Committee.
Cell culture
The method for primary culture of human PTC is described in
detail elsewhere [21]. Briefly, the renal tissue was transported
immediately to the laboratory and decapsulated. The cortex was
dissected from the medulla, finely minced, subjected to collage-
nase digestion (class 2, 383 U/mg; Worthington, Freehold, NJ,
USA) for 30 minutes at 37°C and passed through a 100 mm mesh.
Filtered tubular fragments were resuspended in 50 ml of 45%
Percoll (Pharmacia, Uppsala, Sweden) made isosmotic with dou-
ble-strength Krebs-Henseleit solution (NaCl 108 mmol/liter, KCl
4.9 mmol/liter, CaCl4 2.6 mmol/liter, NaH2PO4 3.1 mmol/liter,
NaHCO3 28 mmol/liter), and centrifuged at 20,000 rpm (48,400 g)
and 4°C for 30 minutes (Beckman J2 to 21 ultracentrifuge). The
lowermost tissue band, containing highly purified populations of
proximal tubule fragments, was carefully removed and washed.
These tubule fragments were resuspended in serum-free, antibi-
otic-free, hormonally-defined media, consisting of 1:1 (vol/vol)
Dulbecco’s modified Eagle’s media and Ham’s F-12 (DMEM/
Ham’s F-12; ICN) supplemented with 5 mg/ml human transferrin
(Sigma, St. Louis, MO, USA), 5 mg/ml (0.87 mmol/liter) bovine
insulin (Sigma), 0.05 mmol/liter hydrocortisone (Sigma), 10 ng/ml
(1.64 nmol/liter) epidermal growth factor (Collaborative Re-
search Inc., Bedford, MA, USA), 50 mmol/liter prostaglandin E1
(Sigma), 50 nmol/liter selenium (Sigma) and 5 pmol/liter tri-
iodothyronine (Sigma). The tubular fragments were plated at a
density of 1.5 mg pellet/cm2 (approximately 5000 to 7000 frag-
ments/cm2) in 75 cm2 flasks (Corning, NY, USA). Media were
changed every 48 hours. The cells were incubated in humidified
95% air/5% CO2 at 37°C and were subcultured at near-confluence
using a seeding density of 4000 cells/cm2. Such cells were desig-
nated passage 1.
Cytologic examination of cytocentrifuge preparations of cul-
tured PTC from all donors failed to reveal any evidence of cellular
atypia. The growth and transport characteristics of these cells
have been previously studied in this laboratory and found to
reproducibly exhibit the features of PTC in vivo. Specifically, these
cells exhibit typical morphology along with intact tight junctions
and polarized transport systems, including pharmacologically dis-
tinct apical and basolateral NHE, phlorizin-inhibitable apical
Na1-glucose transport, parathyroid hormone-inhibitable apical
Na1-phosphate transport, probenecid-inhibitable vectorial or-
ganic anion transport and quinine-inhibitable vectorial organic
cation transport [21].
Experimental protocol
All studies were performed on confluent, quiescent, passage 2
human PTC grown on 24-well culture plates (Nunc, Roskilde,
Denmark) for growth parameter and 22Na1 uptake measure-
ments, or on glass coverslips for microspectrofluorimetry. Quies-
cence was achieved by incubation for 24 hours in basic media
(DMEM/Ham’s F-12 containing 5 mg/ml human transferrin).
Cells were then incubated with basic media containing vehicle
(control), TGF-b1 alone (Sigma), TGF-b1 combined with human
recombinant IGF-I (Collaborative Research Inc.), or IGF-I alone.
The concentration of TGF-b1 employed for these experiments
was determined by preliminary dose-response studies, which
delineated the minimum concentration of TGF-b1 required to
produce a maximal anti-proliferative effect in human PTC. The
IGF-I concentration used (100 ng/ml) has been previously found
in this laboratory to maximally stimulate PTC growth [14]. Unless
otherwise stated, incubations were for 24 hours.
Growth parameter measurements
Growth parameters were measured according to previously
described methods [14]. Twenty-four hours prior to study, 0.15
MBq (4 mCi) of [methyl-3H]-thymidine (37 MBq/ml, 185 GBq/
mmol; Amersham) was added to each ml of control or test media
that was incubated with cells. At the end of the incubation
periods, cells were dislodged with 80 ml/cm2 CR-Dispase (Collab-
orative Research Inc.) for 10 minutes at 37°C. Cells were then
washed three times in phosphate buffered saline (PBS) at 1250 g
and 4°C for five minutes. Aliquots of the cell suspensions were
retained for cell counting in a standard haemocytometer and for
determination of thymidine incorporation by liquid scintillation
counting in a b-counter (1215 Rackbeta II; LKB Wallac, Turku,
Finland).
Cellular protein content was measured in the remaining por-
tions of cell suspensions after cell disruption by a Boy 1000
ultrasound (Rudolf Grauer, Switzerland). Protein concentration
was determined by Bio-Rad protein assay (Bio-Rad, California,
USA), using bovine serum albumin (fraction V, RIA grade;
Sigma) as the standard.
Measurement of sodium hydrogen exchange activity
Microspectrofluorimetry. Microspectrofluorimetric determina-
tion of NHE activity is described in detail elsewhere [14]. Briefly,
confluent monolayers of PTC grown on glass coverslips were
loaded with 5 mmol/liter 29,79-bis(2 carboxyethyl)-5 [6]-carboxy-
fluorescein acetoxymethyl ester (BCECF-AM; Molecular Probes,
Eugene, OR, USA) for 30 minutes at 37°C. Following removal of
residual extracellular dye, the monolayers were mounted on the
stage of a Nikon-Diaphot inverted microscope in a 300 ml
chamber and perfused at a rate of 1.5 ml/min with pre-warmed
(37°C) Na1-containing buffer (135 mmol/liter NaCl, 4 mmol/liter
KCl, 1.2 mmol/liter CaCl2, 0.8 mmol/liter MgCl2, 1 mmol/liter
NaH2PO4, 5 mmol/liter D-glucose, 10 mmol/liter HEPES, pH
7.4). The cells were excited alternately at 430 nm and 490 nm.
BCECF fluorescence was detected at an emission wavelength of
530 nm. After subtraction of background fluorescence values, the
490 nm/430 nm fluorescence intensity ratios were then calculated
and converted into intracellular pH (pHi) measurements using the
high K1/nigericin calibration technique.
Johnson et al: TGFb1 dissociates PTC growth and NHE1602
During each experiment, cells were acidified by perfusion with
20 mmol/liter NH4Cl in Na
1-containing buffer for five minutes
followed by perfusion with Na1-free buffer (135 mmol/liter
N-methyl-D-glucamine, 4 mmol/liter KCl, 1.2 mmol/liter CaCl2,
0.8 mmol/liter MgCl2, 1 mmol/liter NaH2PO4, 5 mmol/liter D-
glucose, 10 mmol/liter HEPES, pH 7.4) for five minutes. The cells
were then perfused with Na1-containing buffer in the presence or
absence of 10 mmol/liter EIPA. The initial rate of pHi recovery
was obtained by calculating the first order derivative of the
Na1-dependent alkalinization curve during the first 60 seconds.
Intrinsic buffer capacities (bi) were determined separately in
cells from each of the control and treatment groups by sequen-
tially pulsing them with isosmotic, Na1-free buffers containing 0,
5, 10 or 20 mmol/liter NH4Cl and measuring the change in pHi.
Regression lines, relating bi to pHi for human PTC between pHi
6.6 and 7.6, were generated. The intracellular buffer capacities for
the PTC used in the pHi recovery experiments were calculated by
interpolation from these regression equations. H1 efflux rates
were determined by multiplying the rates of change in pHi by the
bis at the corresponding pHi values. NHE activities were defined
as the components of H1 efflux that were Na1-dependent and
inhibited by 10 mmol/liter EIPA. This concentration of EIPA has
been previously demonstrated to produce maximal inhibition of
apical NHE in human PTC under basal and mitogen-stimulated
conditions [14].
22Na1 uptake. The method used has been described previously
[14]. Cell culture medium was aspirated and the cells were then
washed and incubated with 200 ml isotonic, Na1-free NH4Cl
buffer (20 mmol/liter NH4Cl, 115 mmol/liter choline chloride, 4
mmol/liter KCl, 1.2 mmol/liter CaCl2, 0.8 mmol/liter MgCl2, 5
mmol/liter D-glucose, 28.3 mmol/liter HEPES, 17.7 mmol/liter
Tris base, pH 7.4) for 15 minutes at 37°C. 22Na1 uptake was
measured at 37°C by removing the Na1-free NH4Cl buffer and
replacing it with 100 ml uptake medium (pH 7.4), containing 135
mmol/liter NaCl, 4 mmol/liter KCl, 1.2 mmol/liter CaCl2, 0.8
mmol/liter MgCl2, 5 mmol/liter D-glucose, 28.3 mmol/liter
HEPES, 17.7 mmol/liter Tris base, 100 mmol/liter ouabain (Sig-
ma) and 0.2 mCi carrier-free 22Na1 (1 mCi/ml; NEN Research
Products, Du Pont, Wilmington, DE, USA) in the presence or
absence of 10 mmol/liter ethylisopropylamiloride (EIPA; Molec-
ular Probes, Eugene, OR, USA). The reaction was stopped at one
minute by aspirating the uptake medium and rapidly washing six
times with 500 ml of ice-cold 0.1 mol/liter MgCl2. Intracellular
22Na1 was then released by lysing the cells with 250 ml of 0.2
mol/liter NaOH. Aliquots were retained for liquid scintillation
counting and protein estimation. Results were expressed as
nmol/mg protein/min. NHE activity was defined as the difference
between 22Na1 uptake in the presence and absence of EIPA, and
has previously been demonstrated by EIPA dose-response curves
to reflect predominantly apical NHE activity [14].
Statistical analysis
All studies were performed in triplicate from PTC cultures
obtained from four to eight separate human donors. Results are
expressed as mean 6 SEM. Statistical differences between groups
were assessed by one-way analysis of variance (ANOVA). Pair-
wise multiple comparisons were made by Fisher’s protected
least-significant differences test. The relationships between bi and
pHi were determined by simple linear regression analysis. Deter-
minations of the intracellular H1-activation kinetics for apical
NHE were made by non-linear regression analysis using the Hill
equation [22]. Analyses were performed using the software pack-
ages Statview version 4.5 (Abacus Concepts Inc., Berkeley, CA,
USA) and Regression version M1.23 (Blackwell Scientific Publi-
cations, Oxford, UK). P values less than 0.05 were considered
significant.
RESULTS
Basal proximal tubule cell DNA synthesis
TGF-b1 induced a concentration-dependent inhibition of PTC
incorporation of thymidine, which reached statistical significance
at 1 ng/ml (Fig. 1). The concentrations at which half-maximal and
maximal inhibition of DNA synthesis occurred were 0.4 and 1
ng/ml, respectively. No changes were detected in cell numbers,
Fig. 1. Effect of transforming growth factor-B1
(TGF-b1) on proximal tubule cell (PTC) DNA
synthesis. Thymidine incorporation was
measured in confluent, quiescent human PTC
incubated for 24 hours in serum-free media
containing various concentrations of TGF-b1, as
indicated. Results represent the mean 6 SEM of
4 experiments, each performed in triplicate.
*P , 0.05 versus control.
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protein contents or apical NHE activities (measured as EIPA-
sensitive apical 22Na1 uptakes) at concentrations of up to 10
ng/ml (104.8 6 6.7%, 97.4 6 10.7% and 100.7 6 19.9% of control
values, respectively, P 5 NS). On the basis of these findings, a
concentration of 1 ng/ml was employed for TGF-b1 in all subse-
quent studies.
To exclude a time-dependent effect of TGF-b1 on apical NHE
activity, time course studies were performed in which PTC were
incubated with 1 ng/ml TGF-b1 for 24, 48 or 72 hours. Thymidine
incorporation rates were significantly inhibited by TGF-b1 at 24
hours (81.8 6 7.9% of control values, P , 0.05) and 48 hours
(81.5 6 8.9% of control values, P , 0.05), but not at 72 hours
(100.4 6 10.1% of control values, P 5 NS). However, apical NHE
activities were not significantly altered at any time point (98.5 6
26.3%, 85.9 6 28.4% and 105.9 6 9.5% of control values,
respectively, P 5 NS). Cellular protein contents were similarly
unaffected (102.5 6 16.9%, 101.1 6 11.3% and 119.6%618.4%,
respectively, P 5 NS).
Growth response of proximal tubule cells to insulin-like growth
factor-1
TGF-b1 significantly inhibited IGF-I-stimulated PTC DNA
synthesis (Fig. 2). Cellular protein content was not altered by
TGF-b1 or IGF-I alone, but was significantly increased when the
two growth factors were combined (Fig. 2). PTC numbers were
not significantly different between any of the study groups
(TGF-b1 alone 94.1 6 5.3% of control, TGF-b1 and IGF-I 93.0 6
7.9%, IGF-I alone 109.4 6 8.6%, P 5 NS).
Compared with control conditions, EIPA-sensitive H1 efflux
rates were unchanged in the presence of TGF-b1 alone, but were
significantly and comparably increased by IGF-I, both in the
presence and absence of TGF-b1 (Fig. 3). Na
1-dependent H1
efflux was abolished by 10 mmol/liter EIPA in all groups. Kinetic
studies of NHE activities with respect to intracellular [H1] in all
groups best fitted an allosteric model (Fig. 4). TGF-b1 did not
alter NHE kinetics under basal conditions. Co-incubation of
TGF-b1 and IGF-I resulted in a significant increase in Vmax
(16.51 6 1.36 vs. control 8.27 6 0.60 mmol/liter/min, P , 0.05)
without alteration in Km. This kinetic mode of activation is
identical to that previously reported for PTC exposed to IGF-I
alone [14].
When NHE activities were measured by the independent
method of 22Na1 uptake measurement, TGF-b1 was again found
to have no effect under basal conditions (2.19 6 0.19 vs. control
2.20 6 0.23 nmol/mg protein/min, P 5 NS) or following IGF-I
Fig. 2. Effect of transforming growth factor-B1
(TGF-b1) on insulin-like growth factor-1 (IGF-
I)-induced human proximal tubule cell (PTC)
growth. Confluent monolayers of human PTC
were incubated for 24 hours in serum-free
media containing either vehicle (control, u), 1
ng/ml TGF-b1 (f), 1 ng/ml TGF-b1 plus 100
ng/ml IGF-I (o), or 100 ng/ml IGF-I (M) alone.
Thymidine incorporation and cellular protein
contents (expressed per cell) were measured
and normalized against control values. Results
represent the mean 6 SEM of 8 experiments,
each performed in triplicate. *P , 0.05 versus
control. #P , 0.05 versus TGF-b1 alone.
Fig. 3. Effect of transforming growth factor B1 (TGF-b1) on basal and
insulin-like growth factor-1 (IGF-I)-stimulated sodium hydrogen ex-
change (NHE) activity. H1 efflux rates following acid loading were
measured in human PTC exposed for 24 hours to vehicle (control), 1 ng/ml
TGF-b1, 1 ng/ml TGF-b1 and 100 ng/ml IGF-I, or 100 ng/ml IGF-I alone.
Rates were measured in the presence and absence of 10 mmol/liter EIPA.
Results represent the mean 6 SEM of 7 experiments, each performed in
triplicate. **P , 0.0001 versus control and TGF-b1 alone.
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stimulation (3.63 6 0.63 vs. IGF-I alone 3.67 6 0.50, P 5 NS, both
P , 0.05 vs. control). The EIPA-resistant components of 22Na1
uptake by PTC were equivalent among all groups (control 0.71 6
0.14, TGF-b1 0.84 6 0.22, TGF-b1 and IGF-I 0.78 6 0.14, IGF-I
0.63 6 0.12 nmol/mg protein/day, P 5 NS).
DISCUSSION
The present study demonstrates that incubation of confluent,
primary cultures of human PTC with TGF-b1 significantly inhibits
cellular proliferation without alteration in either cellular protein
content or NHE activity. In view of the compelling evidence
invoking roles for both TGF-b1 and IGF-I in animal models of
physiological and pathological renal growth [2, 3, 7, 8, 23], the
combination of TGF-b1 with IGF-I results in a distinct hypertro-
phic growth pattern in PTC, which contrasts with the anti-
proliferative response observed with the addition of TGF-b1
alone and the mitogenic response seen with IGF-I alone. How-
ever, TGF-b1 modifies the growth response to IGF-I without
altering IGF-I-induced activation of apical NHE. Moreover, the
NHE activation kinetics for cells exposed to the combination of
TGF-b1 and IGF-I reveals a predominant increase in Vmax,
similar to that previously demonstrated for IGF-I alone [14].
Hence, the combination of TGF-b1 and IGF-I dissociates mito-
genesis and NHE activity.
Activation of NHE has been widely postulated as a possible
mechanism of inducing PTC growth [16, 19]. Although most
studies have focused on the link between cellular growth and the
ubiquitous “housekeeping” NHE isoform (NHE1), which is found
on the basolateral aspects of PTC and other epithelial cells, a
recent study performed in our laboratory [14] demonstrated that
apical NHE isoforms (NHE3 and/or NHE2), which represent the
major entry route for sodium into PTC [14, 24], are also activated
by growth factors and possibly underpin the subsequent growth
response [14]. Enhanced NHE activity and augmented proximal
tubular Na1 reabsorption take place within 24 hours of a hyper-
trophic stimulus and prior to any demonstrable cell growth [1, 12,
16, 17]. Moreover, stimulation of NHE by a variety of mitogens is
known to be a widespread phenomenon in many non-renal cells
[19, 25], while blockade of NHE with amiloride analogs inhibits
cellular proliferation [19, 24]. The temporal sequence and ubiq-
uity of these events has led to the hypothesis that NHE activation
transduces the signal for cellular proliferation [18, 19].
However, the converse situation, assessing whether cellular
NHE activity is inhibited in the presence of anti-proliferative
factors, has seldom been studied. Zaragoza, Battle-Tracy and
Owen [26] argued that cellular proliferation is linked to changes in
ion flux by showing that heparin engenders concentration-depen-
dent and proportional decreases in both NHE activities and
proliferation rates in vascular smooth muscle cells. However, the
current report clearly demonstrates that inhibition of PTC DNA
synthesis is not necessarily associated with suppression of NHE
activity. This confirms a previous finding by Fine et al [12], who
demonstrated that BSC-1 growth inhibitor, now considered to be
identical to TGF-b2 [27], has no effect on amiloride-sensitive
22Na1 uptake by rabbit PTC. Unfortunately, the results of that
study have been difficult to interpret because NHE measurements
were performed on cells in suspension, which have subsequently
been shown to poorly reflect the properties of NHE activities in
adherent, polarized epithelial cells [28]. Moreover, BSC-1 growth
inhibitor was found to paradoxically stimulate, rather than inhibit,
PTC proliferation under basal conditions, a finding which has not
been reproduced by ourselves or by other investigators [4, 10, 29,
30] using the TGF-b1 isoform.
In the presence of IGF-I, the current study also found that
TGF-b1 could block stimulation of PTC DNA synthesis without
affecting IGF-I-induced augmentation of NHE activity. Similar
results have also been reported for TGF-b2 on the effects of
insulin and hydrocortisone on rabbit PTC [12], although a strong
association was still observed between increased cellular protein
content and augmented NHE activity. It was consequently argued
that NHE activation might be a necessary requirement for renal
hypertrophy, rather than hyperplasia. However, our findings that
IGF-I stimulates NHE activity without altering cellular protein
content indicate that PTC NHE activity can be dissociated from
hypertrophy, as well as from hyperplasia. This is supported by a
report by Golchini et al [31] in which NH4Cl increased cellular
Fig. 4. Rate of H1 efflux as a function of
intracellular [H1]. Calculated effluxes from
human proximal tubule cells (PTC) following
acute cell acidification were found to be
dependent on intracellular [H1] for control
(M), TGF-b1 alone (F) and TGF-b1 1 IGF-I
(L). For clarity of presentation, data from PTC
exposed to IGF-I alone have been omitted, but
were found to be associated with an increase in
Vmax, as described previously [14].
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protein content in an animal proximal tubule cell line (JTC),
despite concomitant suppression of NHE activity by amiloride.
The findings in the present study of inhibition of both basal and
mitogen-stimulated PTC growth without alteration of NHE activ-
ity complement and extend the observations by other investigators
that these processes are dissociated by selective inhibition of NHE
activity. For example, Grantham and coworkers [32] noted that
hexamethylene amiloride, an amiloride analog with low affinity
for sodium channels and high affinity for NHE, does not limit
compensatory renal hypertrophy in unilaterally nephrectomized
mice. Unfortunately, the investigators did not confirm inhibition
of NHE activity. Mackovic-Basic et al [33] observed that mutant
LLC-PK1 cells with NHE activities of less than 5% of that of
control cells could still be stimulated to significantly increase their
protein contents following administration of 1 mmol/liter insulin
or 1 nmol/liter IGF-I. Although NHE activity was also augmented
by approximately 50% in the mutant cells, the absolute activity
was less than that under control conditions. Recognizing the
limitations of performing studies in mutated, immortalized cell
lines, subsequent studies by the same group [34] have further
shown that denervation of remnant rat kidneys at the time of
contralateral nephrectomy prevents stimulation of NHE activity
in rat proximal tubule brush border vesicles, but does not affect
either the course or extent of compensatory renal hypertrophy, as
determined by measurement of kidney weight. However, the
absence of an increase in NHE activity in brush border membrane
vesicles, which possibly lack the full complement of cytosolic
NHE-associated regulatory molecules, does not exclude NHE
activation in native, intact proximal tubule cells [24, 35].
Dissociation of growth and NHE activity in human PTC in the
current study also does not rule out a growth-regulatory role for
sodium flux due to transport pathways other than NHE. Walsh-
Reitz, Toback and Holley [36] reported that TGF-b2 attenuated
the EGF- and serum-induced increases in intracellular sodium
content in BSC-1 cells. Since the amount of peptide required to
inhibit growth was twice that required for inhibition of sodium
influx, they argued that cell sodium content could be a necessary
but insufficient signal to stimulate DNA synthesis. In addition,
TGFb1 has been shown to inhibit Na
1,K1-ATPase [37, 38] in
rabbit proximal tubule cells and diminish Na1-phosphate cotrans-
port, but not Na1-amino acid transport, in OK cells [39]. It should
be noted however, that in human proximal tubule cells in the
present study, EIPA-resistant Na1 uptake was not altered by
TGF-b1. The measurements for this parameter were uniformly
small though, and the method may not have been sufficiently
sensitive to allow comment on Na1 uptake by pathways other than
NHE.
Interestingly, in keeping with the results of other studies [29,
30], neither TGF-b1 nor IGF-I induced an increase in cellular
protein content on their own. However, the combination of the
two growth factors resulted in a significant hypertrophic response.
A similar increase in cellular protein content has been reported
for the combination of TGF-b1 with other mitogens, such as
insulin [12] and EGF [13]. This may be related to a TGF-b1-
induced block at the G1/S restriction point [40] following mitogen-
stimulated entry into the cell cycle. Alternatively, both IGF-I and
TGF-b1 are known to inhibit proteolysis [11, 41], such that the
combination of the two may sufficiently block intracellular protein
degradation to generate a measurable increase in cellular protein
content.
Predominant PTC hypertrophy with minimal hyperplasia [15]
and enhanced proximal tubule Na1 reabsorption (via apical
NHE) characterize many physiological and pathological renal
growth states, such as compensatory hypertrophy or diabetic
nephropathy [1, 17]. Our results suggest that in vivo renal growth,
and its associated changes in proximal tubule Na1 transport, may
be caused by the integrated actions of both TGFb1 and IGF-I.
Indeed, overexpression of both growth factors has now been
documented in a large number of experimental and human kidney
disorders [3, 8, 23].
In conclusion, the results of the present study suggest that
altered NHE activity is not a necessary concomitant of changes in
tubular cell proliferation. Moreover, the combination of predom-
inant PTC hypertrophy and early enhanced proximal tubule Na1
reabsorption found in many human renal pathophysiologic con-
ditions may be linked to the integrated actions of TGF-b1 and
IGF-I.
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